To study the bioequivalence of Clavulanate Potassium and Amoxicillin (1:7) dispersible tablets, a randomized cross over study was conducted in 18 healthy volunteers. A single oral dose of 1000 mg Clav ulanate Pot...To study the bioequivalence of Clavulanate Potassium and Amoxicillin (1:7) dispersible tablets, a randomized cross over study was conducted in 18 healthy volunteers. A single oral dose of 1000 mg Clav ulanate Potassium and Amoxicillin (1:7) dispersible tablets (Tested formulation, T) or Augmentin syrup (Reference formulation, R). Concentrations in plasma were determined with high performance liquid chromatography. The main paramaters of T were: for Clavulanate Potassium and Amoxicillin, C max : 2.46±1.11 μg/m l and 18.81±7.26 μg/ml, T max : 1.12±0.23h and 1.30±0.34h, AUC (0 - 6 h) : 5.18±2.24 μg·h/ml and 45.09±14.53 μg·h/ml, t 1/2 : 1.43±0.44 h and 1.09±0.22 h., respectively. The relative bioavailability of T to R were 9 6.5±19.2 % and 98.4±26.1 % , respectively. Statistical analysis showed that th e two formulations were bioequivalent.展开更多
OBJECTIVE To compare the pharmacokinetics and pharmacodynamics of PEG30-rhG-CSF administered to beagle dogs at three different dosages with PEG20-rhG-CSF administered at one dosage, and to provide an experimental basi...OBJECTIVE To compare the pharmacokinetics and pharmacodynamics of PEG30-rhG-CSF administered to beagle dogs at three different dosages with PEG20-rhG-CSF administered at one dosage, and to provide an experimental basis for clinical trials.METHODS Beagle dogs received single, subcutaneous doses of PEG30-rhG-CSF at 100, 200 and 400 μg/kg or PEG20-rhG-CSF at 200 μg/kg. PEG30-rhG-CSF and PEG20-rhG-CSF concentrations in serum were analyzed using an enzymeqinked immunosorbent assay （ELISA）. WBC, ANC and PLT counts of whole blood samples were measured using fully automated analytic instrumentation. Pharmacokinetic and pharmacodynamic parameters were calculated using DAS 2.0 statistical analysis software.METHODS Beagle dogs received single, subcutaneous doses of PEG30-rhG-CSF at 100, 200 and 400 μg/kg or PEG20-rhG-CSF at 200μg/kg. PEG30-rhG-CSF and PEG20-rhG-CSF concentrations in serum were analyzed using an enzyme-linked immunosorbent assay （ELISA）. WBC, ANC and PLT counts of whole blood samples were measured using fully automated analytic instrumentation. Pharmacokinetic and pharmacodynamic parameters were calculated using DAS 2.0 statistical analysis software. RESULTS The pharmacokinetic parameters of PEG30-rhG-CSF calculated from the serum concentration data determined by ELISA were as follows： the mean elimination half-life （t1/2ke） was 40.6 h （33.5-45.4 h）; the mean time to reach peak concentration （Tmax） was 19.2 h （11.7-24.0 h）; the drug clearance from the serum （CL） was decreased with increasing doses; the peak concentration （Cmax） and the area under the serum concentration-time curve （AUC） were increased with increasing doses. For PEG20-rhG- CSF, the half-life was shorter （12 h） and Tmax was achieved much earlier （10 h） relative to PEG30-rhG-CSF. The AUC of PEG30- rhG-CSF was much greater than that of PEG20-rhG-CSF, and the relative bioavailability with a subcutaneous injection was 158.7%. Administration of single doses of PEG30-rhG-CSF resulted in substantial i展开更多
目的分离铜绿假单胞菌噬菌体,比较其形态、裂菌特性并测定其裂解谱,根据裂解谱筛选出裂解百分比最高的噬菌体,并测定其最佳感染复数和体内代谢动力学等基本生物学特性。方法取兰州市区污水样品经0.22μm滤膜过滤,用双层琼脂平板培养法...目的分离铜绿假单胞菌噬菌体,比较其形态、裂菌特性并测定其裂解谱,根据裂解谱筛选出裂解百分比最高的噬菌体,并测定其最佳感染复数和体内代谢动力学等基本生物学特性。方法取兰州市区污水样品经0.22μm滤膜过滤,用双层琼脂平板培养法分离、纯化铜绿假单胞菌噬菌体并测定其裂解谱;纯化后的噬菌体进行扫描电镜观察;评估裂解谱后筛选出裂解百分比最高的为PaP106,分别按照感染复数(MOI)=10^(-1)、10^(-2)、10^(-3)、10^(-4)、10^(-5)、10^(-6)、10^(-7)比例加入PaP106和铜绿假单胞菌共培养后测定噬菌体滴度,确定其最佳感染复数;不同途径(腹腔、肌肉、皮下)给小鼠注射1×10^(10)pfu/m L PaP106 100μL,分别于0.5、1、3、6、12、24、36 h测定小鼠血液、肝脏、脾脏组织中噬菌体的浓度,分析噬菌体体内代谢动力学变化。结果共分离到6株形态不同的铜绿假单胞菌噬菌体,对铜绿假单胞菌耐药菌株的裂解百分比为25%—75%,其中PaP106噬菌体对铜绿假单胞菌耐药菌株的裂解百分比最高(75%),PaP106噬菌体的最佳感染复数为1×10^(-6),腹腔注射PaP106噬菌体后,其在血液、肝脏、脾脏的达峰时间短于皮下注射和肌肉注射途径。结论在分离得到的6株铜绿假单胞菌噬菌体中,PaP106噬菌体裂解性强、裂解谱宽,腹腔注射噬菌体后血液、肝脏、脾脏的分布及达峰时间最快,为今后临床治疗感染多重耐药铜绿假单胞菌提供了理论基础。展开更多
文摘To study the bioequivalence of Clavulanate Potassium and Amoxicillin (1:7) dispersible tablets, a randomized cross over study was conducted in 18 healthy volunteers. A single oral dose of 1000 mg Clav ulanate Potassium and Amoxicillin (1:7) dispersible tablets (Tested formulation, T) or Augmentin syrup (Reference formulation, R). Concentrations in plasma were determined with high performance liquid chromatography. The main paramaters of T were: for Clavulanate Potassium and Amoxicillin, C max : 2.46±1.11 μg/m l and 18.81±7.26 μg/ml, T max : 1.12±0.23h and 1.30±0.34h, AUC (0 - 6 h) : 5.18±2.24 μg·h/ml and 45.09±14.53 μg·h/ml, t 1/2 : 1.43±0.44 h and 1.09±0.22 h., respectively. The relative bioavailability of T to R were 9 6.5±19.2 % and 98.4±26.1 % , respectively. Statistical analysis showed that th e two formulations were bioequivalent.
基金National High Technology Research and Development Program of China(No.2007BAI14IB04)Major State Basic Research Development Program(No.2004CB518902)
文摘OBJECTIVE To compare the pharmacokinetics and pharmacodynamics of PEG30-rhG-CSF administered to beagle dogs at three different dosages with PEG20-rhG-CSF administered at one dosage, and to provide an experimental basis for clinical trials.METHODS Beagle dogs received single, subcutaneous doses of PEG30-rhG-CSF at 100, 200 and 400 μg/kg or PEG20-rhG-CSF at 200 μg/kg. PEG30-rhG-CSF and PEG20-rhG-CSF concentrations in serum were analyzed using an enzymeqinked immunosorbent assay （ELISA）. WBC, ANC and PLT counts of whole blood samples were measured using fully automated analytic instrumentation. Pharmacokinetic and pharmacodynamic parameters were calculated using DAS 2.0 statistical analysis software.METHODS Beagle dogs received single, subcutaneous doses of PEG30-rhG-CSF at 100, 200 and 400 μg/kg or PEG20-rhG-CSF at 200μg/kg. PEG30-rhG-CSF and PEG20-rhG-CSF concentrations in serum were analyzed using an enzyme-linked immunosorbent assay （ELISA）. WBC, ANC and PLT counts of whole blood samples were measured using fully automated analytic instrumentation. Pharmacokinetic and pharmacodynamic parameters were calculated using DAS 2.0 statistical analysis software. RESULTS The pharmacokinetic parameters of PEG30-rhG-CSF calculated from the serum concentration data determined by ELISA were as follows： the mean elimination half-life （t1/2ke） was 40.6 h （33.5-45.4 h）; the mean time to reach peak concentration （Tmax） was 19.2 h （11.7-24.0 h）; the drug clearance from the serum （CL） was decreased with increasing doses; the peak concentration （Cmax） and the area under the serum concentration-time curve （AUC） were increased with increasing doses. For PEG20-rhG- CSF, the half-life was shorter （12 h） and Tmax was achieved much earlier （10 h） relative to PEG30-rhG-CSF. The AUC of PEG30- rhG-CSF was much greater than that of PEG20-rhG-CSF, and the relative bioavailability with a subcutaneous injection was 158.7%. Administration of single doses of PEG30-rhG-CSF resulted in substantial i
文摘目的分离铜绿假单胞菌噬菌体,比较其形态、裂菌特性并测定其裂解谱,根据裂解谱筛选出裂解百分比最高的噬菌体,并测定其最佳感染复数和体内代谢动力学等基本生物学特性。方法取兰州市区污水样品经0.22μm滤膜过滤,用双层琼脂平板培养法分离、纯化铜绿假单胞菌噬菌体并测定其裂解谱;纯化后的噬菌体进行扫描电镜观察;评估裂解谱后筛选出裂解百分比最高的为PaP106,分别按照感染复数(MOI)=10^(-1)、10^(-2)、10^(-3)、10^(-4)、10^(-5)、10^(-6)、10^(-7)比例加入PaP106和铜绿假单胞菌共培养后测定噬菌体滴度,确定其最佳感染复数;不同途径(腹腔、肌肉、皮下)给小鼠注射1×10^(10)pfu/m L PaP106 100μL,分别于0.5、1、3、6、12、24、36 h测定小鼠血液、肝脏、脾脏组织中噬菌体的浓度,分析噬菌体体内代谢动力学变化。结果共分离到6株形态不同的铜绿假单胞菌噬菌体,对铜绿假单胞菌耐药菌株的裂解百分比为25%—75%,其中PaP106噬菌体对铜绿假单胞菌耐药菌株的裂解百分比最高(75%),PaP106噬菌体的最佳感染复数为1×10^(-6),腹腔注射PaP106噬菌体后,其在血液、肝脏、脾脏的达峰时间短于皮下注射和肌肉注射途径。结论在分离得到的6株铜绿假单胞菌噬菌体中,PaP106噬菌体裂解性强、裂解谱宽,腹腔注射噬菌体后血液、肝脏、脾脏的分布及达峰时间最快,为今后临床治疗感染多重耐药铜绿假单胞菌提供了理论基础。
